Clinical trials: COVID-19
COVID-19
[14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects
This trial adopts a single-center, single-dose, single-period, non-randomized, open-label study design. It is planned to enroll 6~8 healthy male subjects, and each subject receives single oral administration of drug solution…
- Trial name
- NCT05754411
- Testing
- [14C]STI-1558
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
Covid19, COVID-19 Pneumonia
imPulse™ Una Infrasound-to-ultrasound E-stethoscope
This study generates robust, uniform clinical data across emerging COVID-19 strains to train ML/AI algorithms of the Sponsor's imPulse™ Una infrasound-to-ultrasound e-stethoscope for digital diagnostic feature synthesis of…
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT04941209
- Testing
- imPulse™ Una infrasound-to-ultrasound e-stethoscope, (PPA >95%) FDA EUA RT-PCR, HR-CT-scan
- Where
- 3 sites in Democratic Republic of the Congo, India and 1 more
- Volunteers
- 702 people
- Sponsor
- Level 42 AI, Inc.
COVID-19
Safety and Efficacy of C21 in Subjects With COVID-19
This is a randomised, double-blind, placebo-controlled phase 2 trial investigating the safety and efficacy of C21 in subjects who are hospitalised with COVID-19 infection, but not in need of mechanical invasive or non-invasive…
- Trial name
- NCT04452435
- Testing
- C21
- Where
- 9 sites in India, United Kingdom
- Volunteers
- 206 people
- Sponsor
- Vicore Pharma AB
Long COVID Symptoms
Vagal Approaches on Long COVID-19
The purpose of this study is to explore whether two general wellness products, alone or combined, can support individuals experiencing Long COVID symptoms.
- Trial name
- NCT07190105
- Testing
- Sonocea Sonic Augmentation Technology (SAT), Truvaga Electrical Vagus Nerve Stimulator
- Where
- United States
- Volunteers
- 546 people
- Sponsor
- Leidos Life Sciences
Covid19
Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects
Prospective samples will be collected to evaluate the agreement between a EUA RT-PCR test as the comparator method against the Nanomix eLab® system.
- Trial name
- NCT04667442
- Testing
- Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Nanomix
COVID-19
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
- Trial name
- NCT04377620
- Testing
- Ruxolitinib
- Where
- 36 sites in United States, Russia
- Volunteers
- 211 people
- Sponsor
- Incyte Corporation
SARS-CoV-2, Influenza, Human
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal…
- Conditions
- SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome
- Trial name
- NCT06684379
- Testing
- PRS CK STORM
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PEACHES BIOTECH
COVID
Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
GC004 is a Phase I trial to evaluate the safety and the immune responses of a therapeutic vaccine in SARS-CoV-2 infected patients.
- Trial name
- NCT04428073
- Testing
- Covax-19™
- Volunteers
- 32 people
- Sponsor
- GeneCure Biotechnologies
COVID-19, SARS-CoV-2
LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study
COVID-19 is the infectious disease caused by the novel coronavirus known as SARS-CoV-2, that appeared in 2019. The World Health Organisation (WHO) declared the novel coronavirus a pandemic on 11 March 2020.
- Trial name
- LIVE (NCT05282017)
- Where
- 9 sites in Brazil, Colombia and 3 more
- Volunteers
- 792 people
- Sponsor
- AstraZeneca
Covid19
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
- Trial name
- NCT05046561
- Testing
- STRI Formula
- Where
- 13 sites in United States
- Volunteers
- 598 people
- Sponsor
- Eyecheck, Inc.
Corona Virus Infection
Sarilumab COVID-19
Primary Objective: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult participants hospitalized with severe or critical Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04327388
- Testing
- Sarilumab SAR153191
- Where
- 47 sites in Argentina, Brazil and 9 more
- Volunteers
- 420 people
- Sponsor
- Sanofi
COVID-19
Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)
This phase III clinical trial is an endpoint-driven randomized, double-blind, parallel-controlled, multicenter clinical trial, and around 13,000 subjects aged 18 years and above who have previously received 1 dose of…
- Trial name
- NCT05124561
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- Volunteers
- healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Long COVID
Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infection
The project is described as a Phase 1 Clinical Safety Study intended to provide preliminary assessments of the safety, tolerability, and secondarily to be vigilant for signals of amelioration of symptoms associated with…
- Trial name
- NCT05669261
- Testing
- Adipose Tissue Harvest, ATCell
- Volunteers
- 20 people
- Sponsor
- American CryoStem Corporation
COVID-19
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants with early stage coronavirus disease 2019…
- Trial name
- NCT04539262
- Testing
- Remdesivir (RDV)
- Where
- 28 sites in United States
- Volunteers
- 156 people
- Sponsor
- Gilead Sciences
Long COVID
Feasibility of Cannabidiol for the Treatment of Long COVID
This is an open label, phase 2 clinical trial to assess the feasibility of a cannabidiol (CBD) dominant medicinal cannabis for the treatment of Long COVID.
- Trial name
- NCT04997395
- Testing
- MediCabilis Cannabis sativa 50
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Bod Australia
COVID-19
Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
The purpose of this study is to assess the immunogenicity and safety of the investigational SCB-2019 vaccine, administered as a booster dose, to adults who: Received primary series with one of the selected authorized or…
- Trial name
- NCT05188677
- Testing
- Candidate vaccine, SCB-2019, Comirnaty Vaccine, Vaxzevria Vaccine
- Where
- 2 sites in Philippines
- Volunteers
- 1,831 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Covid19, SARS-CoV Infection
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2…
- Conditions
- Covid19, SARS-CoV Infection, Corona Virus Infection
- Trial name
- NCT04668339
- Testing
- ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming
- Where
- 15 sites in United States, Singapore
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Covid19
Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection
Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection
- Trial name
- NCT04488575
- Testing
- EDP1815
- Where
- 4 sites in United States, Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- Evelo Biosciences, Inc.
SARS-CoV2 Infection
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
The purpose of this study is to evaluate the efficacy, safety and immunogenicity of GX-19N in healthy individuals who have received one of COVID-19 vaccine authorized for emergency use.
- Trial name
- NCT05067946
- Testing
- GX-19N
- Volunteers
- healthy volunteers welcome
- Sponsor
- Genexine, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.